Inactive Instrument

Cancer Genetics, Inc.

Equities

CGIX

US13739U2033

Cancer Genetics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2019

May 20, 2019 at 05:02 pm

Cancer Genetics, Inc. announced earnings results for the first quarter ended March 31, 2019. For the first quarter, the company announced sales was USD 6.839 million compared to USD 7.667 million a year ago. Operating loss was USD 2.918 million compared to USD 4.947 million a year ago. Net loss was USD 4.617 million compared to USD 4.456 million a year ago. Basic loss per share was USD 0.09 compared to USD 0.16 a year ago.

Latest news about Cancer Genetics, Inc.

Cancer Genetics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-16	CI
Cancer Genetics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-30	CI
Cancer Genetics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2020	21-03-31	CI
Cancer Genetics, Inc. has Changed its Ticker to VYNT from CGIX	21-03-31	CI
Cancer Genetics, Inc. has Changed its Name to Vyant Bio, Inc	21-03-30	CI
Cancer Genetics, Inc.(NasdaqCM:CGIX) dropped from NASDAQ Composite Index	21-03-30	CI
StemoniX Inc. completed the acquisition of Cancer Genetics, Inc. from a group of shareholders in a reverse merger transaction.	21-03-29	CI
Cancer Genetics : Secures Shareholder Nod for Proposed StemoniX Merger	21-03-25	MT
Cancer Genetics, Inc. Appoints Roland J. Carrillo as the Vice President of Business Development	21-03-18	CI
Cancer Genetics : to Raise $17.5 Million in Common Stock Offering	21-02-11	MT
Cancer Genetics, Inc. announced that it has received $10.000012 million in funding	21-01-31	CI
Cancer Genetics, Inc. announced that it expects to receive $10.000012 million in funding	21-01-27	CI
Certain Common Stock of Cancer Genetics, Inc. are subject to a Lock-Up Agreement Ending on 27-JAN-2021.	21-01-26	CI
Certain Stock Option of Cancer Genetics, Inc. are subject to a Lock-Up Agreement Ending on 27-JAN-2021.	21-01-26	CI
Certain Warrants of Cancer Genetics, Inc. are subject to a Lock-Up Agreement Ending on 27-JAN-2021.	21-01-26	CI
Cancer Genetics, Inc. Announces Executive Changes	20-11-20	CI
Cancer Genetics : Earnings Flash (CGIX) CANCER GENETICS Reports Q3 Revenue $1.57M	20-11-12	MT
Cancer Genetics : Earnings Flash (CGIX) CANCER GENETICS Reports Q3 Revenue $1.57M	20-11-12	MT
Cancer Genetics, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020	20-11-12	CI
Cancer Genetics, Inc. Announces Departure of Glenn Miles as Chief Financial Officer, Effective November 16, 2020	20-10-19	CI
Cancer Genetics, Inc. Announces Resignation of Dr. Raju S.K. Chaganti	20-09-30	CI
Cancer Genetics, Inc. and StemoniX Inc. Announce Joint Proof of Concept Program	20-09-03	CI
StemoniX Inc. entered into a definitive merger agreement to acquire Cancer Genetics, Inc. from a group of shareholders for $55.1 million in a reverse merger transaction.	20-08-23	CI
Cancer Genetics, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2020	20-08-13	CI
Cancer Genetics Mulls Strategic Options	20-06-01	CI

Chart Cancer Genetics, Inc.

Duration

Period

More charts

Company Profile

Cancer Genetics, Inc. is engaged in the field of personalized medicine, enabling precision medicine in the field of oncology through its diagnostic products and services and molecular markers. Through its subsidiary, the Company offers preclinical test systems. The Company offers discovery services to the pharmaceutical industry, biotechnology companies and academic research centers. The Company provides the tools and testing methods for companies and researchers to identify new molecular- and biomarker-based indicators for disease and to determine the pharmacogenomics, toxicity and efficacy of therapeutic candidate compounds. Its discovery services include development of both xenograft and syngeneic animal models, toxicology and genetic toxicology services, pharmacology testing, pathology services, and validation of biomarkers for diseases including cancers. It also provides consulting, guidance and preparation of samples.

Sector

More about the company